Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

317 questions · 341 findings · 38 reviews · Vascular

No studies found 55 · 16.1%GRADE not reported 32 · 9.4%Very low 58 · 17%Low 117 · 34.3%Moderate 57 · 16.7%High 22 · 6.5%

PTFE vs PTFE with vein cuff

Limb salvage · people with peripheral vascular disease requiring below‐knee femoro‐popliteal bypass surgery

PTFE showed no clear difference in limb salvage (24 months) compared with PTFE with vein cuff (low certainty).

1 finding from 1 review

ASA + high‐dose LMWH vs ASA + low‐dose LMWH or UFH

Subcutaneous bruises · people with antiphospholipid antibodies and no history of thrombosis

ASA + high‐dose LMWH showed no clear difference in subcutaneous bruises compared with ASA + low‐dose LMWH or UFH (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs low molecular weight heparin

VTE‐related mortality4 · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in VTE‐related mortality at 3 months compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs low molecular weight heparin

Major bleedingd (3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in major bleedingd (3 months) compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs low molecular weight heparin

All‐cause mortality (7 days ‐ 3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in all‐cause mortality (7 days ‐ 3 months) compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs low molecular weight heparin

Symptomatic recurrent VTE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent VTE at 3 months compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs low molecular weight heparin

Symptomatic recurrent DVT at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent DVT at 3 months compared with low molecular weight heparin (low certainty).

1 finding from 1 review